Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Levy, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
Johns Hopkins Hospital, Baltimore, MDfellowship09/2009Neuroimmunology
Johns Hopkins Hospital, Baltimore, MDresidency06/2008Neurology
Baylor College of Medicine, Houston, TXMD, PhD05/2004Medicine/Neuroscience
Univ of Pennsylvania, Philadelphia, PABA06/1997Biology

Overview
Michael Levy, MD, PhD, is an Associate Professor in Neurology who was recently recruited to lead the research unit in the new Division of Neuroimmunology at the Massachusetts General Hospital. His mission is to build a combined clinical and research neuroimmunology program to develop therapies for patients with autoimmune diseases of the central nervous system. Dr. Levy moved from Baltimore, MD, where was on the faculty at Johns Hopkins University since 2009 and Director of the Neuromyelitis Optica Clinic.

Clinically, Dr. Levy specializes in taking care of children and adults with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease and acute disseminated encephalomyelitis. In addition to four monthly clinics, Dr. Levy is the principal investigator on several clinical studies and drug trials for these conditions. In the laboratory, his research focuses on the development of animal models of neuromyelitis optica with the goal of tolerization as a sustainable long term treatment.

Mentoring
Available: 11/14/19, Expires: 08/31/20

This is a retrospective analysis of the experience of using IVIG for treatment of MOG antibody disease.

The role of the student in this project is to contact our patients with MOG antibody disease, collect information about the safety and efficacy of IVIG therapy, analyze the data and publish a manuscript of the findings, all under the supervision of the principal investigator.


Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01AI130548 (LEVY, MICHAEL) May 25, 2018 - Apr 30, 2023
    NIH/NIAID
    Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis Optica
    Role: Principal Investigator
  2. K08NS078555 (LEVY, MICHAEL) May 1, 2013 - Apr 30, 2018
    NIH/NINDS
    immunopathogenesis of NMO-IgG and AQP4-specific T cells in neuromyelitis optica
    Role: Principal Investigator

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Levy M. Interleukin-6 receptor blockade for the treatment of NMOSD. Lancet Neurol. 2020 May; 19(5):370-371. PMID: 32333886.
    Citations:    
  2. Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, Watt KD, Port JD, Basu R, Acosta A, Hanouneh I, Gara N, Shah M, Mundi M, Clark M, Grothe K, Storm AC, Levy MJ, Abu Dayyeh BK. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020 Apr 30. PMID: 32360804.
    Citations:    
  3. Malikowski T, Levy MJ, Gleeson FC, Storm AC, Vargas Valls EJ, Topazian MD, Abu Dayyeh BK, Iyer PG, Rajan E, Gores GJ, Roberts L, Chandrasekhara V. EUS-FNA is effective for lymph node staging in patients with cholangiocarcinoma. Hepatology. 2019 Dec 20. PMID: 31860935.
    Citations:    
  4. Storm AC, Levy MJ, Kaura K, Abu Dayyeh BK, Cleary SP, Kendrick ML, Truty MJ, Vargas EJ, Topazian M, Chandrasekhara V. Acute and early EUS-guided transmural drainage of symptomatic postoperative fluid collections. Gastrointest Endosc. 2020 May; 91(5):1085-1091.e1. PMID: 31843369.
    Citations:    
  5. Malikowski T, Lehrke HD, Henry MR, Gleeson FC, Alberts SR, Kendrick ML, Lennon RJ, McWilliams RR, Takahashi N, Topazian MD, Gara N, Abu Dayyeh BK, Chandrasekhara V, Chari ST, Iyer PG, Rajan E, Storm AC, Wang KK, Levy MJ. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Pancreatology. 2020 Jan; 20(1):110-115. PMID: 31759906.
    Citations:    
  6. Kaura K, Bazerbachi F, Sawas T, Levy MJ, Martin JA, Storm AC, Wise KB, Reisenauer CJ, Abu Dayyeh BK, D Topazian M, Petersen BT, Schiller HJ, Chandrasekhara V. Surgical outcomes of ERCP-guided transpapillary gallbladder drainage versus percutaneous cholecystostomy as bridging therapies for acute cholecystitis followed by interval cholecystectomy. HPB (Oxford). 2019 Nov 01. PMID: 31685380.
    Citations:    
  7. Lu J, Roy B, Anderson M, Leggett CL, Levy MJ, Pogue B, Hasan T, Wang KK. Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. J Biomed Opt. 2019 11; 24(11):1-11. PMID: 31741351.
    Citations:    
  8. Kaura K, Sawas T, Bazerbachi F, Storm AC, Martin JA, Gores GJ, Abu Dayyeh BK, Topazian MD, Levy MJ, Petersen BT, Chandrasekhara V. Cholangioscopy Biopsies Improve Detection of Cholangiocarcinoma When Combined with Cytology and FISH, but Not in Patients with PSC. Dig Dis Sci. 2020 May; 65(5):1471-1478. PMID: 31571103.
    Citations:    
  9. Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang J, Ogbuokiri E, Cowley NJ, Pellegrini N, Murphy OC, Mealy MA, Prince JL, Levy M, Calabresi PA, Saidha S. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler. 2019 Jul 31; 1352458519864928. PMID: 31364464.
    Citations:    
  10. Bulut E, Shoemaker T, Karakaya J, Ray DM, Mealy MA, Levy M, Izbudak I. MRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified Etiology. AJNR Am J Neuroradiol. 2019 08; 40(8):1427-1432. PMID: 31296526.
    Citations:    
  11. Pardo S, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E, Levy M. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019 08; 33:A1-A2. PMID: 31324299.
    Citations:    
  12. Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR. Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2019 09; 6(5):e583. PMID: 31355319.
    Citations:    
  13. Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR. Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2019 Sep; 6(5). PMID: 31454765.
    Citations:    
  14. Cotzomi E, Stathopoulos P, Lee CS, Ritchie AM, Soltys JN, Delmotte FR, Oe T, Sng J, Jiang R, Ma AK, Vander Heiden JA, Kleinstein SH, Levy M, Bennett JL, Meffre E, O'Connor KC. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain. 2019 06 01; 142(6):1598-1615. PMID: 31056665.
    Citations:    
  15. Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019 Jun; 98(25):e15944. PMID: 31232925.
    Citations:    
  16. Mealy MA, Kozachik SL, Levy M. Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Manag Nurs. 2019 12; 20(6):580-591. PMID: 31103517.
    Citations:    
  17. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 08 15; 381(7):614-625. PMID: 31050279.
    Citations:    
  18. Mealy MA, Boscoe A, Caro J, Levy M. Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. Int J MS Care. 2019 May-Jun; 21(3):129-134. PMID: 31191178.
    Citations:    
  19. Waubant E, Giovannoni G, Hawkes C, Lechner-Scott J, Levy M. Three suggestions to decrease the financial burden of MS treatments. Mult Scler Relat Disord. 2019 May; 30:A1. PMID: 30987755.
    Citations:    
  20. Lechner-Scott J, Giovannoni G, Hawkes C, Levy M, Waubant E. One size doesn't fit all. Mult Scler Relat Disord. 2019 06; 31:A1-A2. PMID: 31159999.
    Citations:    
  21. Levy M, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E. Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease. Mult Scler Relat Disord. 2019 Apr; 29:A1-A2. PMID: 30885376.
    Citations:    
  22. Levy M. Expanding the spectrum of MOG antibody disease. Mult Scler. 2020 Apr; 26(4):515-516. PMID: 30931729.
    Citations:    
  23. Salama S, Khan M, Pardo S, Izbudak I, Levy M. MOG antibody-associated encephalomyelitis/encephalitis. Mult Scler. 2019 10; 25(11):1427-1433. PMID: 30907249.
    Citations:    
  24. Bulut E, Karakaya J, Salama S, Levy M, Huisman TAGM, Izbudak I. Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. AJNR Am J Neuroradiol. 2019 04; 40(4):726-731. PMID: 30846436.
    Citations:    
  25. Levy M. Ten years of iron chelation in a patient with superficial siderosis. Neurol Sci. 2019 Sep; 40(9):1947-1949. PMID: 30834458.
    Citations:    
  26. Mealy MA, Newsome SD, Kozachik SL, Levy M, Smith TJ. Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis. Int J MS Care. 2019 Mar-Apr; 21(2):76-80. PMID: 31049038.
    Citations:    
  27. Salama S, Pardo S, Levy M. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019 May; 30:231-235. PMID: 30825703.
    Citations:    
  28. Miranda-Acuña J, Rivas-Rodríguez E, Levy M, Ansari M, Stone R, Patel V, Amezcua L. Rituximab during pregnancy in neuromyelitis optica: A case report. Neurol Neuroimmunol Neuroinflamm. 2019 03; 6(2):e542. PMID: 30800724.
    Citations:    
  29. Hawkes C, Giovannoni G, Lechner-Scott J, Levy M, Waubant E. Multiple Sclerosis and Vitamin D - Caviar or a Dog's Dinner? Mult Scler Relat Disord. 2019 Feb; 28:A1-A2. PMID: 30823982.
    Citations:    
  30. Salama S, Khan M, Levy M, Izbudak I. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord. 2019 Apr; 29:15-22. PMID: 30658259.
    Citations:    
  31. Giovannoni G, Hawkes C, Levy M, Lechner-Scott J, Waubant E. Should our treatment target in MS include the intrathecal plasma cell response? Mult Scler Relat Disord. 2019 01; 27:A1-A2. PMID: 30642567.
    Citations:    
  32. Jones MV, Levy M. Effect of CXCR2 Inhibition on Behavioral Outcomes and Pathology in Rat Model of Neuromyelitis Optica. J Immunol Res. 2018; 2018:9034695. PMID: 30648122.
    Citations:    
  33. Banerjee A, Ng J, Coleman J, Ospina JP, Mealy M, Levy M. Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Mult Scler Relat Disord. 2019 Feb; 28:60-63. PMID: 30554039.
    Citations:    
  34. Mealy MA, Mossburg SE, Kim SH, Messina S, Borisow N, Lopez-Gonzalez R, Ospina JP, Scheel M, Yeshokumar AK, Awad A, Leite MI, Arango JJ, Paul F, Palace J, Kim HJ, Levy M. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019 Feb; 28:64-68. PMID: 30554040.
    Citations:    
  35. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing]. Nervenarzt. 2018 Dec; 89(12):1388-1399. PMID: 30264269.
    Citations:    
  36. Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018 11 27; 91(22):e2089-e2099. PMID: 30366977.
    Citations:    
  37. Waubant E, Giovannoni G, Hawkes C, Levy M. Vaccines and disease-modifying treatments. Mult Scler Relat Disord. 2018 11; 26:A1-A2. PMID: 30573174.
    Citations:    
  38. Levy M, Giovannoni G, Hawkes C, Waubant E. Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica. Mult Scler Relat Disord. 2018 10; 25:A1-A2. PMID: 30384960.
    Citations:    
  39. Levy M. Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018 Nov; 5(6):e510. PMID: 30345335.
    Citations:    
  40. Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ. Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology. 2018 10 23; 91(17):e1642-e1651. PMID: 30258024.
    Citations:    
  41. Salama S, Marouf H, Ihab Reda M, Mansour AR, ELKholy O, Levy M. Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta. J Neuroimmunol. 2018 11 15; 324:22-25. PMID: 30199734.
    Citations:    
  42. Hawkes CH, Giovannoni G, Levy M, Waubant E. Editors' Welcome. Mult Scler Relat Disord. 2018 08; 24:A1-A2. PMID: 30190056.
    Citations:    
  43. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Paul F, Levy M. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018 Oct; 25:66-72. PMID: 30048919.
    Citations:    
  44. Giovannoni G, Hawkes C, Levy M, Waubant E. Is cognitive impairment in multiple sclerosis reversible? Mult Scler Relat Disord. 2018 07; 23:A1. PMID: 30049507.
    Citations:    
  45. Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, Kister I, Levy M. Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm. 2018 Jul; 5(4):e468. PMID: 29892608.
    Citations:    
  46. Malikowski T, Lehrke HD, Henry MR, Gleeson FC, Topazian MD, Harmsen WS, Takahashi N, Inoue D, Gara N, Abu Dayyeh BK, Chari ST, Iyer PG, Rajan E, Wang KK, Levy MJ. Accuracy of Endoscopic Ultrasound Imaging in Distinguishing Celiac Ganglia From Celiac Lymph Nodes. Clin Gastroenterol Hepatol. 2019 01; 17(1):148-155.e3. PMID: 29857152.
    Citations:    
  47. Mealy MA, Cook LJ, Pache F, Velez DL, Borisow N, Becker D, Arango JAJ, Paul F, Levy M. Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018 Jul; 23:78-82. PMID: 29783157.
    Citations:    
  48. Holroyd KB, Aziz F, Szolics M, Alsaadi T, Levy M, Schiess N. Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: A multicenter, retrospective study. Clin Exp Neuroimmunol. 2018 Aug; 9(3):155-161. PMID: 30090123.
    Citations:    
  49. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018 May 03; 15(1):134. PMID: 29724224.
    Citations:    
  50. Waubant E, Berkowitz A, Giovannoni G, Hawkes C, Levy M. Diagnosing and caring for MS in Haiti. Mult Scler Relat Disord. 2018 05; 22:A1-A2. PMID: 29807822.
    Citations:    
  51. Levy M, Giovannoni G, Hawkes C, Waubant E. Editors' Welcome: Pregnancy and progressive multifocal leukoencephalopathy. Mult Scler Relat Disord. 2018 04; 21:A1-A2. PMID: 29724377.
    Citations:    
  52. Levy MJ, Kipp BR, Milosevic D, Schneider AR, Voss JS, Avula R, Kerr SE, Henry MR, Highsmith E, Liu MC, Gleeson FC. Analysis of Cell-Free DNA to Assess Risk of Tumoremia Following Endoscopic Ultrasound Fine-Needle Aspiration of Pancreatic Adenocarcinomas. Clin Gastroenterol Hepatol. 2018 10; 16(10):1632-1640.e1. PMID: 29526691.
    Citations:    
  53. Majumder S, Mohapatra S, Lennon RJ, Piovezani Ramos G, Postier N, Gleeson FC, Levy MJ, Pearson RK, Petersen BT, Vege SS, Chari ST, Topazian MD, Witzig TE. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. Clin Gastroenterol Hepatol. 2018 12; 16(12):1947-1953. PMID: 29526692.
    Citations:    
  54. Paul F, Murphy O, Pardo S, Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs. 2018 03; 27(3):265-271. PMID: 29465257.
    Citations:    
  55. Giovannoni G, Hawkes C, Levy M, Waubant E. Are the high-costs of MS disease-modifying therapies justified? Mult Scler Relat Disord. 2018 02; 20:A3-A5. PMID: 29579631.
    Citations:    
  56. Hawkes C, Giovannoni G, Levy M, Waubant E. Editors' Welcome. Mult Scler Relat Disord. 2018 02; 20:A1-A2. PMID: 29579630.
    Citations:    
  57. Rustagi T, Gleeson FC, Abu Dayyeh BK, Topazian MD, Levy MJ. Evaluation of Effects of Radiofrequency Ablation of Ex vivo Liver Using the 1-Fr Wire Electrode. J Clin Gastroenterol. 2018 02; 52(2):168-171. PMID: 28263238.
    Citations:    
  58. Mealy MA, Nam TS, Pardo SJ, Pardo CA, Sobreira NL, Avramopoulos D, Valle D, Burns KH, Levy M. Familial monophasic acute transverse myelitis due to the pathogenic variant in VPS37A. Neurol Genet. 2018 Feb; 4(1):e213. PMID: 29473047.
    Citations:    
  59. Giovannoni G, Hawkes C, Levy M, Lublin F, Waubant E. Editors' Welcome. Mult Scler Relat Disord. 2018 01; 19:A1-A2. PMID: 29409600.
    Citations:    
  60. Kessler RA, Li X, Schwartz K, Huang H, Mealy MA, Levy M. Two-year observational study of deferiprone in superficial siderosis. CNS Neurosci Ther. 2018 03; 24(3):187-192. PMID: 29285884.
    Citations:    
  61. Barreras P, Fitzgerald KC, Mealy MA, Jimenez JA, Becker D, Newsome SD, Levy M, Gailloud P, Pardo CA. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology. 2018 01 02; 90(1):e12-e21. PMID: 29196574.
    Citations:    
  62. Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018 Jan 15; 384:96-103. PMID: 29249387.
    Citations:    
  63. Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K, Levy M. Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis. Mult Scler J Exp Transl Clin. 2017 Oct-Dec; 3(4):2055217317740145. PMID: 29270309.
    Citations:    
  64. Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28; 89(22):2238-2244. PMID: 29093070.
    Citations: 2     Fields:    Translation:Humans
  65. Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, Paul F, Wingerchuk DM, Greenberg BM, Kim HJ, Levy M. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018 11; 24(13):1737-1742. PMID: 28857723.
    Citations:    
  66. Kessler RA, Mealy MA, Jimenez-Arango JA, Quan C, Paul F, López R, Hopkins S, Levy M. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. Mult Scler Relat Disord. 2017 Oct; 17:198-201. PMID: 29055457.
    Citations:    
  67. Eaneff S, Wang V, Hanger M, Levy M, Mealy MA, Brandt AU, Eek D, Ratchford JN, Nyberg F, Goodall J, Wicks P. Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017 Oct; 17:116-122. PMID: 29055439.
    Citations:    
  68. Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. 2017 May; 4(3):e339. PMID: 28382320.
    Citations: 7     
  69. Orman G, Wang KY, Pekcevik Y, Thompson CB, Mealy M, Levy M, Izbudak I. Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. AJNR Am J Neuroradiol. 2017 May; 38(5):949-953. PMID: 28302609.
    Citations:    
  70. Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, Levin MH, Verkman AS, Steinman L, Green AJ, Anderson MS, Sobel RA, Zamvil SS. Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proc Natl Acad Sci U S A. 2016 12 20; 113(51):14781-14786. PMID: 27940915.
    Citations:    
  71. Chavarro VS, Mealy MA, Simpson A, Lacheta A, Pache F, Ruprecht K, Gold SM, Paul F, Brandt AU, Levy M. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Dec; 3(6):e286. PMID: 27800532.
    Citations:    
  72. Freund B, Mowry EM. Neuromyelitis optica unmasked by a spinal dural arteriovenous fistula. J Neuroimmunol. 2016 11 15; 300:18-20. PMID: 27806871.
    Citations:    
  73. Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M, Rostasy K. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016 Aug 30; 87(9 Suppl 2):S59-66. PMID: 27572863.
    Citations: 4     Fields:    Translation:Humans
  74. Haseeb A, Abu Dayyeh BK, Levy MJ, Fujii LL, Pearson RK, Chari ST, Gleeson FC, Peterson BT, Swaroop Vege S, Topazian M. Endoscopic Ultrasound-Guided Treatment of Pancreaticocutaneous Fistulas. ACG Case Rep J. 2016 Aug; 3(4):e105. PMID: 27807567.
    Citations:    
  75. Kessler RA, Mealy MA, Levy M. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e269. PMID: 27508210.
    Citations:    
  76. Abboud H, Fernandez HH, Mealy MA, Levy M. Spinal Movement Disorders in Neuromyelitis Optica: An Under-recognized Phenomenon. Mov Disord Clin Pract. 2016 Nov-Dec; 3(6):596-602. PMID: 30838252.
    Citations:    
  77. Hollinger KR, Franke C, Arenivas A, Woods SR, Mealy MA, Levy M, Kaplin AI. Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder. J Neurol Sci. 2016 Mar 15; 362:85-90. PMID: 26944124.
    Citations:    
  78. Kessler RA, Mealy MA, Levy M. Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic. Curr Treat Options Neurol. 2016 Jan; 18(1):2. PMID: 26705758.
    Citations:    
  79. Jurynczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016 Jan; 263(1):140-9. PMID: 26530512.
    Citations: 8     Fields:    Translation:Humans
  80. Mealy MA, Shin K, John G, Levy M. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015 Nov 01; 6(4):413-418. PMID: 26834844.
    Citations:    
  81. Mealy MA, Levy M. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. J Neuroimmunol. 2015 Oct 15; 287:29-30. PMID: 26439958.
    Citations:    
  82. Levy M. The ethics of placebo controlled clinical trials in NMO - A balance of risks. Mult Scler Relat Disord. 2015 Nov; 4(6):512-4. PMID: 26590656.
    Citations:    
  83. Pekcevik Y, Orman G, Lee IH, Mealy MA, Levy M, Izbudak I. What do we know about brain contrast enhancement patterns in neuromyelitis optica? Clin Imaging. 2016 May-Jun; 40(3):573-80. PMID: 26615899.
    Citations:    
  84. Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, Thompson CB, Pardo CA, Calabresi PA, Levy M, Izbudak I. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler. 2016 Mar; 22(3):302-11. PMID: 26209588.
    Citations:    
  85. Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e134. PMID: 26236760.
    Citations: 16     
  86. Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015 Jul; 72(7):815-22. PMID: 26010909.
    Citations: 12     Fields:    Translation:Humans
  87. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14; 85(2):177-89. PMID: 26092914.
    Citations: 269     Fields:    Translation:Humans
  88. Jones MV, Huang H, Calabresi PA, Levy M. Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathol Commun. 2015 May 21; 3:28. PMID: 25990016.
    Citations:    
  89. Mealy MA, Whetstone A, Orman G, Izbudak I, Calabresi PA, Levy M. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci. 2015 Aug 15; 355(1-2):59-63. PMID: 26026942.
    Citations:    
  90. Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler. 2016 Feb; 22(2):185-92. PMID: 25921047.
    Citations:    
  91. Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015 Apr 28; 84(17):1805-15. PMID: 25841026.
    Citations:    
  92. Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, Kim HJ, Asgari N, Sato DK, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul F. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler. 2015 May; 21(6):678-88. PMID: 25662342.
    Citations:    
  93. Jones MV, Fox-Talbot K, Levy M. Evidence for classic complement activity in neuromyelitis optica. Clin Neuropathol. 2014 May-Jun; 33(3):251-2. PMID: 24569172.
    Citations:    
  94. Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014 Jun; 1(1):e5. PMID: 25340061.
    Citations:    
  95. Kimbrough DJ, Mealy MA, Simpson A, Levy M. Predictors of recurrence following an initial episode of transverse myelitis. Neurol Neuroimmunol Neuroinflamm. 2014 Jun; 1(1):e4. PMID: 25340060.
    Citations: 4     
  96. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014 Mar; 71(3):324-30. PMID: 24445513.
    Citations:    
  97. Levy M. Does aquaporin-4-seronegative neuromyelitis optica exist? JAMA Neurol. 2014 Mar; 71(3):271-2. PMID: 24424919.
    Citations:    
  98. Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, Stuve O. Immunopathogenesis of neuromyelitis optica. Adv Immunol. 2014; 121:213-42. PMID: 24388217.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  99. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014 06; 20(7):843-7. PMID: 24099751.
    Citations:    
  100. Saini H, Rifkin R, Gorelik M, Huang H, Ferguson Z, Jones MV, Levy M. Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. BMC Neurol. 2013 Aug 08; 13:104. PMID: 23927715.
    Citations:    
  101. Sydlowski SA, Levy M, Hanks WD, Clark MD, Ackley RS. Auditory profile in superficial siderosis of the central nervous system: a prospective study. Otol Neurotol. 2013 Jun; 34(4):611-9. PMID: 23670174.
    Citations:    
  102. Sotirchos ES, Saidha S, Byraiah G, Mealy MA, Ibrahim MA, Sepah YJ, Newsome SD, Ratchford JN, Frohman EM, Balcer LJ, Crainiceanu CM, Nguyen QD, Levy M, Calabresi PA. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013 Apr 09; 80(15):1406-14. PMID: 23516321.
    Citations:    
  103. Greenberg BM, Wingerchuk D, Mealy M, Levy M. What is the true clinicopathologic spectrum of neuromyelitis optica?-Reply. JAMA Neurol. 2013 Feb; 70(2):272-3. PMID: 23400728.
    Citations:    
  104. Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, Marignier R, Nakashima I, Palace J, de Seze J, Stuve O, Tenembaum SN, Traboulsee A, Waubant E, Weinshenker BG, Wingerchuk DM. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord. 2012 Oct; 1(4):180-187. PMID: 24555176.
    Citations: 40     Fields:    
  105. Jones MV, Collongues N, de Seze J, Kinoshita M, Nakatsuji Y, Levy M. Review of Animal Models of Neuromyelitis Optica. Mult Scler Relat Disord. 2012 Oct; 1(4):174-179. PMID: 24555175.
    Citations:    
  106. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012 Sep; 69(9):1176-80. PMID: 22733096.
    Citations:    
  107. Levy M, Llinas RH. Update on a patient with superficial siderosis on deferiprone. AJNR Am J Neuroradiol. 2012 Jun; 33(6):E99-100. PMID: 22576890.
    Citations:    
  108. Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int. 2012; 2012:460825. PMID: 22363840.
    Citations:    
  109. Mealy MA, Newsome S, Greenberg BM, Wingerchuk D, Calabresi P, Levy M. Low serum vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol. 2012 Mar; 69(3):352-6. PMID: 22083799.
    Citations:    
  110. Levy M, Llinas R. Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. Stroke. 2012 Jan; 43(1):120-4. PMID: 22034002.
    Citations:    
  111. Syc SB, Saidha S, Newsome SD, Ratchford JN, Levy M, Ford E, Crainiceanu CM, Durbin MK, Oakley JD, Meyer SA, Frohman EM, Calabresi PA. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012 Feb; 135(Pt 2):521-33. PMID: 22006982.
    Citations:    
  112. Eckstein C, Saidha S, Levy M. A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol. 2012 May; 259(5):801-16. PMID: 21932127.
    Citations:    
  113. Levy M, Llinas RH. Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis. AJNR Am J Neuroradiol. 2011 Jan; 32(1):E1-2. PMID: 21051507.
    Citations:    
  114. Saini H, Fernandez G, Kerr D, Levy M. Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. J Neuroimmunol. 2010 Apr 15; 221(1-2):68-72. PMID: 20227773.
    Citations:    
  115. Chahal P, Baron TH, Topazian MD, Levy MJ. EUS-guided diagnosis and successful endoscopic transpapillary management of an intrahepatic pancreatic pseudocyst masquerading as a metastatic pancreatic adenocarcinoma (with videos). Gastrointest Endosc. 2009 Aug; 70(2):393-6. PMID: 19394005.
    Citations:    
  116. Levy MJ, Chak A. EUS 2008 Working Group document: evaluation of EUS-guided vascular therapy. Gastrointest Endosc. 2009 Feb; 69(2 Suppl):S37-42. PMID: 19179168.
    Citations:    
  117. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008 May 29; 5:22. PMID: 18510734.
    Citations:    
  118. Gleeson FC, Mangan TF, Levy MJ. Endoscopic ultrasound and endoscopic mucosal resection features of a non-protein losing form of Ménétrier's disease. Clin Gastroenterol Hepatol. 2008 May; 6(5):e24-5. PMID: 18455691.
    Citations:    
  119. Pelaez-Luna M, Levy MJ, Arora AS, Baron TH, Rajan E. Mirizzi syndrome presenting as painless jaundice: a rare entity diagnosed by EUS. Gastrointest Endosc. 2008 May; 67(6):974-5; discussion 975. PMID: 18329028.
    Citations:    
  120. Levy M, Birnbaum J, Kerr D. Finding NMO: neuromyelitis optica in children. Neurology. 2008 Jan 29; 70(5):334-5. PMID: 18227415.
    Citations:    
  121. Pelaez-Luna M, Chari ST, Smyrk TC, Takahashi N, Clain JE, Levy MJ, Pearson RK, Petersen BT, Topazian MD, Vege SS, Kendrick M, Farnell MB. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol. 2007 Aug; 102(8):1759-64. PMID: 17686073.
    Citations:    
  122. Levy M, Turtzo C, Llinas RH. Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol. 2007 Jan; 3(1):54-8; quiz 59. PMID: 17205075.
    Citations:    
  123. Simmons DT, Baron TH, Petersen BT, Gostout CJ, Haddock MG, Gores GJ, Yeakel PD, Topazian MD, Levy MJ. A novel endoscopic approach to brachytherapy in the management of Hilar cholangiocarcinoma. Am J Gastroenterol. 2006 Aug; 101(8):1792-6. PMID: 16780552.
    Citations:    
  124. Norton ID, Petersen BT, Bosco J, Nelson DB, Meier PB, Baron TH, Lange SM, Gostout CJ, Loeb DS, Levy MJ, Wiersema MJ, Pochron N. A randomized trial of endoscopic biliary sphincterotomy using pure-cut versus combined cut and coagulation waveforms. Clin Gastroenterol Hepatol. 2005 Oct; 3(10):1029-33. PMID: 16234050.
    Citations:    
  125. Levy MJ, Clain JE. Evaluation and management of cystic pancreatic tumors: emphasis on the role of EUS FNA. Clin Gastroenterol Hepatol. 2004 Aug; 2(8):639-53. PMID: 15290655.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Levy's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (291)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.